Indivior PLC

Indivior PLC has announced a study suggesting that its medication SUBLOCADE may be a safe treatment option for opioid use disorder during pregnancy, with promising preliminary safety data.

Indivior PLC’s shares surged as the company’s Q1 revenue exceeded expectations, driven by its strong product portfolio and commitment to research and development.

Indivior PLC’s shares have surged following the announcement of robust Q1 revenue and a positive outlook, driven by the company’s commitment to developing innovative treatments for substance use disorders and serious mental illnesses.